EUVIMEDEUVIMED entdecken
Crossref

Atractylenolide-I Alleviates Hyperglycemia-Induced Heart Developmental Malformations through Direct and Indirect Modulation of the STAT3 Pathway

Mengwei Wang, Tong-Hua Zhang, Yunjin Li, Xiaofeng Chen, Qiongyin Zhang, Ying Zheng, Denglu Long, Xin Cheng, An Hong, Xuesong Yang, Guang Wang

Phytomedicine · 2024-07 · 129 · 155698

DOI: 10.1016/j.phymed.2024.155698 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2024-07. Verfasst von Mengwei Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Histology and Embryology, International Joint Laboratory for Embryonic Development & Prenatal Medicine, School of Medicine, Jinan Univers…. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Lactones, Sesquiterpenes, Heart Defects, Congenital. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 98 Literaturangaben. Gefördert von: Guangdong Provincial Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Gestational diabetes could elevate the risk of congenital heart defects (CHD) in infants, and effective preventive and therapeutic medications are currently lacking. Atractylenolide-I (AT-I) is the active ingredient of Atractylodes Macrocephala Koidz (known as Baizhu in China), which is a traditional pregnancy-supporting Chinese herb. PURPOSE: In this study, we investigated the protective effect of AT-I on the development of CHD in embryos exposed to high glucose (HG). STUDY DESIGN AND METHODS: First, systematic review search results revealed associations between gestational diabetes mellitus (GDM) and cardiovascular malformations. Subsequently, a second systematic review indicated that heart malformations were consistently associated with oxidative stress and cell apoptosis. We assessed the cytotoxic impacts of Atractylenolide compounds (AT-I, AT-II, and AT-III) on H9c2 cells and chick embryos, determining an optimal concentration of AT-I for further investigation. Second, immunofluorescence, western blot, Polymerase Chain Reaction (PCR), and flow cytometry were utilized to delve into the mechanisms through which AT-I mitigates oxidative stress and apoptosis in cardiac cells. Molecular docking was employed to investigate whether AT-I exerts cardioprotective effects via the STAT3 pathway. Then, we developed a streptozotocin-induced diabetes mellitus (PGDM) mouse model to evaluate AT-I's protective efficacy in mammals. Finally, we explored how AT-I protects hyperglycemia-induced abnormal fetal heart development through microbiota analysis and untargeted metabolomics analysis. RESULTS: The study showed the protective effect of AT-I on embryonic development using a chick embryo model which rescued the increase in the reactive oxygen species (ROS) and decrease in cell survival induced by HG. We also provided evidence suggesting that AT-I might directly interact with STAT3, inhibiting its phosphorylation. Further, in the PGDM mouse model, we observed that AT-I not only partially alleviated PGDM-related blood glucose issues and complications but also mitigated hyperglycemia-induced abnormal fetal heart development in pregnant mice. This effect is hypothesized to be mediated through alterations in gut microbiota composition. We proposed that dysregulation in microbiota metabolism could influence the downstream STAT3 signaling pathway via EGFR, consequently impacting cardiac development and formation. CONCLUSIONS: This study marks the first documented instance of AT-I's effectiveness in reducing the risk of early cardiac developmental anomalies in fetuses affected by gestational diabetes. AT-I achieves this by inhibiting the STAT3 pathway activated by ROS during gestational diabetes, significantly reducing the risk of fetal cardiac abnormalities. Notably, AT-I also indirectly safeguards normal fetal cardiac development by influencing the maternal gut microbiota and suppressing the EGFR/STAT3 pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

STAT3 Transcription FactorLactonesSesquiterpenesHeart Defects, CongenitalHyperglycemiaApoptosisOxidative StressDiabetes, GestationalAnimalsFemaleChick EmbryoPregnancyMiceSignal TransductionDiabetes Mellitus, ExperimentalRatsCell LineAtractylodesMolecular Docking SimulationHumans

Stichwörter der Autor:innen

Atractylenolide-IGestational diabetesGut microbiotaHeart Developmental MalformationsSTAT3 Pathway

Substanzen

STAT3 Transcription FactorLactonesSesquiterpenesatractylenolide IStat3 protein, mouse

Autor:innen und Institutionen

  • Division of Histology and Embryology, International Joint Laboratory for Embryonic Development & Prenatal Medicine, School of Medicine, Jinan University, Guangzhou 510632, China; Department of Cell Biology, College of L…
  • Division of Histology and Embryology, International Joint Laboratory for Embryonic Development & Prenatal Medicine, School of Medicine, Jinan University, Guangzhou 510632, China; Shenzhen Traditional Chinese Medicine Ho…
  • Division of Histology and Embryology, International Joint Laboratory for Embryonic Development & Prenatal Medicine, School of Medicine, Jinan University, Guangzhou 510632, China; Key Laboratory for Regenerative Medicine…
  • The First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
  • Division of Histology and Embryology, International Joint Laboratory for Embryonic Development & Prenatal Medicine, School of Medicine, Jinan University, Guangzhou 510632, China.
  • Department of Cell Biology, College of Life Science and Technology, Jinan University; National Engineering Research Center of Genetic Medicine; Guangdong Provincial Key Laboratory of Bioengineering Medicine; Guangdong P…

Förderung

  • Guangdong Provincial Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Wang, M., Zhang, T. H., Li, Y., Chen, X., Zhang, Q., Zheng, Y., Long, D., Cheng, X., Hong, A., Yang, X., & Wang, G. (2024). Atractylenolide-I Alleviates Hyperglycemia-Induced Heart Developmental Malformations through Direct and Indirect Modulation of the STAT3 Pathway. Phytomedicine, 129, 155698. https://doi.org/10.1016/j.phymed.2024.155698

Vancouver

Wang M, Zhang TH, Li Y, Chen X, Zhang Q, Zheng Y, et al. Atractylenolide-I Alleviates Hyperglycemia-Induced Heart Developmental Malformations through Direct and Indirect Modulation of the STAT3 Pathway. Phytomedicine. 2024;129:155698. doi:10.1016/j.phymed.2024.155698

BibTeX
@article{Wang2024,
  author = {Wang, Mengwei and Zhang, Tong-Hua and Li, Yunjin and Chen, Xiaofeng and Zhang, Qiongyin and Zheng, Ying and Long, Denglu and Cheng, Xin and Hong, An and Yang, Xuesong and Wang, Guang},
  title = {Atractylenolide-I Alleviates Hyperglycemia-Induced Heart Developmental Malformations through Direct and Indirect Modulation of the STAT3 Pathway},
  journal = {Phytomedicine},
  year = {2024},
  volume = {129},
  pages = {155698},
  doi = {10.1016/j.phymed.2024.155698}
}
Kostenlos starten →